Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Cytokine mediators of chronic graft-versus-host disease
Kelli P.A. MacDonald, … , Bruce R. Blazar, Geoffrey R. Hill
Kelli P.A. MacDonald, … , Bruce R. Blazar, Geoffrey R. Hill
Published June 30, 2017
Citation Information: J Clin Invest. 2017;127(7):2452-2463. https://doi.org/10.1172/JCI90593.
View: Text | PDF
Review Series

Cytokine mediators of chronic graft-versus-host disease

  • Text
  • PDF
Abstract

Substantial preclinical and clinical research into chronic graft-versus-host disease (cGVHD) has come to fruition in the last five years, generating a clear understanding of a complex cytokine-driven cellular network. cGVHD is mediated by naive T cells differentiating within IL-17–secreting T cell and follicular Th cell paradigms to generate IL-21 and IL-17A, which drive pathogenic germinal center (GC) B cell reactions and monocyte-macrophage differentiation, respectively. cGVHD pathogenesis includes thymic damage, impaired antigen presentation, and a failure in IL-2–dependent Treg homeostasis. Pathogenic GC B cell and macrophage reactions culminate in antibody formation and TGF-β secretion, respectively, leading to fibrosis. This new understanding permits the design of rational cytokine and intracellular signaling pathway–targeted therapeutics, reviewed herein.

Authors

Kelli P.A. MacDonald, Bruce R. Blazar, Geoffrey R. Hill

×

Figure 1

Cytokines and signaling pathways associated with the effector populations of cGVHD.

Options: View larger image (or click on image) Download as PowerPoint
Cytokines and signaling pathways associated with the effector population...
(A) T effector cells respond to MHC/peptide on antigen presenting cells (APC) and, in the context of IL-6–, IL-23–, and IL-21–stimulated STAT3 phosphorylation, transcribe RORC to drive Th17 and Tc17 differentiation with secretion of IL-17 and related cytokines. IL-12 stimulation promotes T cell–specific T-box transcription factor (TBET) transcription and IFN secretion that signals in an autocrine fashion to enhance Th1 differentiation. Tbet expression and IFN-γ secretion are also characteristic of Th17/Tc17 cells after BMT. (B) Tregs respond to antigen within MHC class II and concurrent TGF-β and IL-2 signaling, which promotes STAT5 phosphorylation, SMAD signaling, and subsequent FOXP3 transcription. Immune regulation by secreted IL-10 and TGF-β ensues. (C) Tfh, identified by ICOS, CXCR5, and PD-1 expression, respond to antigen presented within MHC class II in the context of IL-6, IL-27, and IL-21 stimulation to drive STAT3 phosphorylation and BCL6 transcription, with subsequent secretion of IL-21. (D) BAFF and IL-21 drive GC B cell expansion and, in the context of B cell receptor signaling, subsequent SYK and BTK transcription promotes survival and allo- and autoantibody secretion. BLNK, B cell linker; NFAT, nuclear factor of activated T-cells; BCR, B cell receptor; PLC, phospholipase C.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts